We are thrilled to share the announcement today that Digistain® are 1 of 4 FINALISTS for the 2024 Nature Spin-off Prize
Over 150 innovative technologies were diligently evaluated by a world-class panel of leading scientists so we are very proud that our novel approach to breastcancer diagnostics has been recognised by this prestigious award panel.
Traditional methods of identifying biomarkers to predict breast cancer recurrence risk are slow and expensive. Established biomarkers are very difficult to measure in a lab setting meaning an accurate risk recurrence test is unavailable to 95% of breast cancer patients around the world meaning chemotherapy is their first line of defense.
By transforming the analysis of key biomarkers from a long costly manual wet-lab process to a rapid affordable AI-enabled solution Digistain promises to eliminate global breast cancer care inequalities.
